Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Revisão |
| Language: | English |
| Published: |
2014
|
| Online Access: | https://doi.org/10.1517/14728222.2014.960843 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|